Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | GLENMARK Glenmark Pharmaceuticals Limited Pharma · Mid | APLLTD Alembic Pharmaceuticals Limited Pharma · Mid | AJANTPHARM Ajanta Pharma Limited Pharma · Large | GLAXO GlaxoSmithKline Pharmaceuticals Limited Pharma · Large |
|---|---|---|---|---|
| Final Score | 65 | 35 | 54 | 60 |
| Verdict | UNDERVALUED | WATCHLIST | FAIR VALUE | UNDERVALUED |
| Style | Premium Compounder | WATCHLIST | Premium Compounder | Premium Compounder |
| Piotroski | 8/9 | 8/9 | 8/9 | 8/9 |
| Valuation | 1/30 | 6/30 | 4/30 | 4/30 |
| Growth | 23/25 | 4/25 | 13/25 | 11/25 |
| Quality | 20/20 | 2/20 | 17/20 | 20/20 |
| Balance Sheet | 10/15 | 13/15 | 11/15 | 12/15 |
| Cash Flow | 6/10 | 5/10 | 4/10 | 7/10 |
| Price | ₹2,209.6 | ₹731.5 | ₹3,017.2 | ₹2,194.7 |
| P/E | 20.80 | 20.10 | 35.10 | 36.20 |
| P/B | 5.85 | 2.58 | 8.20 | 16.30 |
| ROE | 30.50% | 13.40% | 25.40% | 48.40% |
| ROCE | 39.80% | 12.60% | 32.30% | 65.10% |
| Debt / Equity | 0.06 | 0.25 | 0.06 | 0.02 |
| FCF Yield | 3.52% | 1.89% | 0.27% | 3.51% |
| Dividend Y | 0.11% | 1.48% | 0.94% | 2.61% |
| Altman Z | 6.46 | 5.24 | 8.92 | 8.62 |
| Promoter % | 46.65% | 69.74% | 66.25% | 75.00% |
| Mkt Cap (₹Cr) | 61421.00 | 14654.00 | 37091.00 | 36995.00 |
| Graham # | ₹635.56 | ₹472.47 | ₹829.71 | ₹429.38 |
| Fair PE | 42.0 | 4.2 | 42.3 | 42.0 |
| MoS % | -9.0% | -406.2% | +15.6% | +14.6% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startGLENMARK133
APLLTD70
AJANTPHARM105
GLAXO86